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CNS accumulation of regulatory B cells is
VLA-4-dependent
ABSTRACT
Objective: To investigate the role of very late antigen-4 (VLA-4) on regulatory B cells (Breg) in CNS
autoimmune disease.
Methods: Experimental autoimmune encephalomyelitis (EAE) was induced in mice selectively defi-
cient for VLA-4 on B cells (CD19cre/a4f/f) by immunization with myelin oligodendrocyte glyco-
protein (MOG) peptide (p)35–55 or recombinant human (rh) MOG protein. B-cell and T-cell
populations were examined by flow cytometry and immunohistochemistry. Breg were evaluated
by intracellular IL-10 staining of B cells and, secondly, by coexpression of CD1d and CD5.
Results: As previously reported, EAE was less severe in B-cell VLA-4-deficient vs control
CD19cre mice when induced by rhMOG, a model that is B-cell-dependent and leads to efficient
B-cell activation and antibody production. Paradoxically, B-cell VLA-4-deficient mice developed
more severe clinical disease than control mice when EAE was induced with MOG p35-55,
a B-cell-independent encephalitogen that does not efficiently activate B cells. Peripheral T-cell
and humoral immune responses were not altered in B-cell VLA-4-deficient mice. In MOG
p35-55-induced EAE, B-cell VLA-4 deficiency reduced CNS accumulation of B but not T cells.
Breg were detected in the CNS of control mice with MOG p35-55-induced EAE. However, more
severe EAE in B-cell VLA-4-deficient mice was associated with virtual absence of CNS Breg.
Conclusions: Our results demonstrate that CNS accumulation of Breg is VLA-4-dependent and
suggest that Breg may contribute to regulation of CNS autoimmunity in situ. These observations
underscore the need to choose the appropriate encephalitogen when studying how B cells con-
tribute to pathogenesis or regulation of CNS autoimmunity. Neurol Neuroimmunol Neuroinflamm
2016;3:e212; doi: 10.1212/NXI.0000000000000212
GLOSSARY
Breg 5 regulatory B cells; EAE 5 experimental autoimmune encephalomyelitis; ICS 5 intracellular cytokine staining; IgG 5
immunoglobulin G; IL 5 interleukin; MOG 5 myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NMO 5 neuromy-
elitis optica; rhMOG 5 recombinant extracellular domain of human myelin oligodendrocyte glycoprotein protein; Treg 5
regulatory T cells; VLA-4 5 very late antigen-4.
Very late antigen-4 (VLA-4; a4b1), the target of natalizumab, is expressed on T cells, B cells,
and other peripheral blood myeloid-derived mononuclear cells, and is required for migration
across the blood–brain barrier. In a previous study, we demonstrated that B-cell a4/VLA-4
expression is important in the pathogenesis of CNS autoimmunity. Selective inhibition of
VLA-4 expression on B cells impeded CNS B-cell accumulation, recruitment of other leuko-
cytes, and susceptibility to experimental autoimmune encephalomyelitis (EAE). These findings
suggested that the clinical benefit of natalizumab in treatment of relapsing-remitting multiple
sclerosis (MS) may, in part, be related to its ability to block B-cell trafficking into the CNS.1
Like T cells, B cells can exhibit proinflammatory or anti-inflammatory activities. In our
earlier study, EAE was induced by immunization with recombinant extracellular domain of
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human myelin oligodendrocyte glycoprotein
(MOG) protein (rhMOG), a B-cell-dependent
encephalitogen that leads to proinflammatory
B-cell activation and production of pathogenic
MOG-specific antibodies.2 In contrast, EAE
induction by encephalitogenic myelin peptides,
including MOG peptide (p) 35–55, does not
promote substantial B-cell activation or anti-
body production3; B-cell-deficient mice are
completely susceptible to myelin peptide-
induced EAE.4,5 Further, depletion of B cells
by anti-CD20 treatment exacerbates MOG
p35-55-induced EAE.3,6 Thus, B cells can have
a key role in regulation of CNS autoimmunity.
In this regard, it is now recognized that regula-
tory B cells (Breg), defined primarily by expres-
sion of the anti-inflammatory cytokine
interleukin (IL)–10,6 may suppress EAE. In
this investigation, we examined MOG p35-
55-induced EAE in B-cell VLA-4-deficient
mice and observed that its severity was greater
in these mice than in control mice with normal
B-cell VLA-4 expression. B-cell VLA-4 defi-
ciency did not influence peripheral T-cell or
B-cell immune modulation. Therefore, we
tested the hypothesis that CNS accumulation
of Breg is also VLA-4-dependent and that the
greater EAE severity in B-cell VLA-4-deficient
mice might reflect fewer CNS Breg. In contrast
to control mice, MOG p35-55-induced EAE
in B-cell VLA-4-deficient mice was associated
with absence of CNS Breg. These findings
demonstrate that CNS Breg accumulation is
VLA-4-dependent and suggest that Breg may
also participate in modulation of CNS autoim-
munity in situ.
METHODS Mice. C57BL/6 a4flox/flox mice (referred to as a4f/f)
were provided by Dr. Thalia Papayannopoulou from the University
of Washington, Seattle.7 C57BL/6 CD19cre mice were purchased
from the Jackson Laboratory (Bar Harbor, ME).8 CD19cre and
a4f/f mice were used as controls.1 All studies were approved by the
UCSF Institutional Animal Care and Use Committee and were in
accordance with the US Public Health Service’s Policy on Humane
Care and Use of Laboratory Animals.
Antigen. Mouse MOG p35-55 (MEVGWYRSPFSRVVH-
LYRNGK) was synthesized by Genemed Synthesis (San Antonio,
TX). rhMOG was provided by Dr. C.C.A. Bernard, Monash
University, Clayton, Australia, and was produced, purified, and
refolded as previously reported.2
EAE induction and analysis. EAE was induced in 8- to 12-
week-old mice by immunization with 100 mg MOG p35-55 or
rhMOG in complete Freund’s adjuvant containing 200 mg
Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit,
MI) on day 0. Mice received 200 ng Bordetella pertussis toxin
(List Biological Laboratories, Campbell, CA) IP on days 0 and
2. Mice were observed daily for clinical EAE.2 Histology and
immunohistochemistry analyses were performed as previously
described.1
Cell isolation and flow cytometric analysis. Splenic and
CNS mononuclear cells were isolated after perfusion with
phosphate-buffered saline as described previously.2 Anti-mouse
FcRIIB/FcRIIIA monoclonal antibody (2.4G2; BD Biosciences,
San Jose, CA) was used to block nonspecific staining. Live/Dead
Fixable Aqua Dead Cell Stain kit was used for viable cell
discrimination, and CountBright counting beads (both Thermo
Fisher Scientific, Waltham, MA) for absolute cell number
quantification. Antibodies to mouse CD19 PerCP-Cy5.5
(eBio1D3), CD4 APC-Cy7 (RM4-5), CD1d FITC (1B1), and
CD11b PE-Cy7 (M1/70) were purchased from eBioscience (San
Diego, CA). Antibodies to B220 (CD45R) FITC (RA3-6B2) and
CD45 APC (30-F11) were purchased from BD Biosciences and
CD5 PE-Cy7 (53-7.3) from BioLegend (San Diego, CA).
Isotype- and fluorochrome-matched control antibodies were
used to assess nonspecific staining for CD1d (immunoglobulin
G [IgG] 2b k FITC; BD Biosciences) and CD5 (IgG2a k APC;
BioLegend). Analysis was performed on a BD Biosciences
LSRFortessa flow cytometer using FACSDiva 8.0 software (BD
Biosciences) and FlowJo version 10.0.8.
Intracellular cytokine staining (ICS). ICS for T-cell cyto-
kines was performed as described,2 using the Cytofix/Cytoperm
Plus fixation/permeabilization kit (BD Biosciences), and antibod-
ies to CD4 PE-Cy7 (RM4-5), IL-17A PerCP-Cy5.5 (eBio17B7),
and interferon-g APC (XMG1.2) (all eBioscience). For staining
of regulatory T cells (Treg), the FoxP3 staining buffer set
(eBioscience) and antibodies to CD4 PerCP-Cy5.5 (RM4-5),
CD25 APC (PC61.5), and FoxP3 PE (FJK-16 s) were used.
Intracellular IL-10 expression was analyzed by flow cytometry
as previously described,9 using the Cytofix/Cytoperm Plus
fixation/permeabilization kit (BD Biosciences). The following
antibodies were used: CD19 PerCP-Cy5.5 (eBio1D3), CD45
PE-Cy7 (30-F11), CD11b APC-Cy7 (M1/70), IL-10 APC
(JES5-16E3) (all from eBioscience), and B220 (CD45R) FITC
(RA3-6B2) (BD Biosciences). An isotype- and fluorochrome-
matched control antibody (IgG2b k APC; eBioscience) was
used to assess nonspecific staining for IL-10.
Detection of anti-MOG antibodies. Anti-MOG p35-55
and anti-rhMOG IgG were measured with a noncommercial
ELISA as described,2 using MOG p35-55 or rhMOG and
horseradish peroxidase–labeled goat anti-mouse IgG (Thermo
Fisher Scientific).
Statistical analysis. Prism software v6.0b (GraphPad, La Jolla,
CA) was used for all statistical analyses. A value of p # 0.05 was
considered statistically significant.
RESULTS B cells in CD19cre/a4f/f mice are selec-
tively deficient in cell surface VLA-4 expression.1
When immunized with rhMOG, these mice are less
susceptible to rhMOG-induced EAE (figure 1A).1 In
contrast, MOG p35-55-induced EAE is more severe
in CD19cre/a4f/f mice than in control mice (figure
1B). As we observed for EAE induced by rhMOG in
CD19cre/a4f/f mice,1 peripheral Th1 and Th17
responses to MOG p35-55 were not significantly
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affected by VLA-4 deficiency (figure e-1, A and B,
at Neurology.org/nn). No detectable difference in the
frequency of peripheral CD41CD251FoxP31
Treg was observed in MOG p35-55-induced EAE
that could explain the greater severity in CD19cre/
a4f/f mice (figure e-1, C and D). Unlike MOG
protein, which activates B cells and stimulates robust
anti-MOG antibody titers, immunization of wild-type
mice withMOG peptide does not efficiently activate B
cells or elicit strong antibody responses.2,3 Similarly, we
observed that immunization with MOG p35-55
elicited only a weak antibody response (figure 1C),
while immunization with rhMOG induced a high
titer of anti-MOG antibodies (figure 1D). However,
B-cell VLA-4 deficiency did not influence antibody
responses to either MOG p35-55 or rhMOG. Thus,
B-cell VLA-4 deficiency did not significantly alter
peripheral CD41 T-cell or humoral responses to
MOG p35-55 or to rhMOG.
Whether the paradoxical exacerbation of MOG
p35-55-induced EAE in CD19cre/a4f/f mice re-
flected immune changes within the CNS was also
evaluated by flow cytometry, histology, and immu-
nohistochemistry. As with rhMOG-induced EAE in
CD19cre/a4f/f mice,1 there was a substantial reduc-
tion of CNS-infiltrating B cells in MOG p35-55-
induced EAE, whereas there was no significant
difference in accumulation of CNS T cells (figure 2,
A and B). The frequencies of proinflammatory CNS
Th1 and Th17 cells in CD19cre/a4f/f and control
mice with MOG p35-55-induced EAE were not sta-
tistically different, although Th17 cells tended to be
higher in the CD19cre/a4f/f mice (figure 2C). Simi-
larly, there was no detectable difference in the
Figure 1 Influence of B-cell very late antigen-4 (VLA-4) deficiency on experimental autoimmune
encephalomyelitis (EAE) induced by recombinant extracellular domain of human myelin
oligodendrocyte glycoprotein protein (rhMOG) or myelin oligodendrocyte glycoprotein (MOG) p35-55
(A) CD19cre/a4f/f (n5 24 mice) and control mice (n5 23 mice) were immunized with 100 mg rhMOG. (B) CD19cre/a4f/f (n5
16 mice) and control mice (n 5 14 mice) were immunized with 100 mg MOG p35-55. Cumulative data from 2 independent
experiments are shown in (A) and (B). Results represent mean disease score6 standard error of the mean. *p# 0.05; **p#
0.01; ***p # 0.001; Mann-Whitney U test. Serum immunoglobulin G (IgG) antibodies against MOG p35-55 (C) and rhMOG
(D) were detected by ELISA. Values represent optical density (OD) at 450 nm. CD19cre/a4f/f or control mice (n 5 3 mice/
group) were immunized with 100 mg MOG p35-55 (C) or 100 mg rhMOG (D). Serum, collected at the end of the experiment,
was diluted 1:300 (C, left panel) or 1:9,000 (C, right panel, D) before analysis. ns5 not significant; unpaired t test withWelch
correction.
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Figure 2 B-cell very late antigen-4 (VLA-4) deficiency reduced CNS accumulation of B cells, but not
proinflammatory or regulatory T cells (Treg), in myelin oligodendrocyte glycoprotein (MOG)
p35-55-induced experimental autoimmune encephalomyelitis (EAE)
CD19cre/a4f/f or control mice were immunized with MOG p35-55. Analyses were performed 14 days after immuni-
zation. (A) CNS-infiltrating CD191 B cells (gated on viable CD45hi lymphocytes) were collected at peak disease. Flow
cytometry plots show 1 representative mouse each (n 5 5–6 mice/group; pooled from 2 independent experiments).
**p # 0.01; Mann-Whitney U test. (B) Immunohistochemistry for T (CD31) and B (B2201) cells in CNS infiltrates. B
cells were not detected in spinal cord meningeal and inflammatory foci in CD19cre/a4f/f mice with EAE (upper left
panel), whereas B cells were detected in CD19cre control mice (upper right panel, arrows). There were comparable
T-cell infiltrates in inflammatory foci in corresponding adjacent serial sections (lower panels). Each panel shows a
spinal nerve root. Scale bar, 30 mm, applies to the 4 panels. Semiquantitative analysis of n 5 6 CD19cre/a4f/f mice
Continued
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frequency of CNS Treg between CD19cre/a4f/f and
control mice with MOG p35-55-induced EAE (fig-
ure 2D). Meningeal, parenchymal, and total CNS
inflammatory foci were not different between
CD19cre/a4f/f and control mice (figure e-2).
We next examined whether B-cell VLA-4 defi-
ciency influenced CNS accumulation of Breg. Two
approaches were used. First, we evaluated for the pres-
ence of IL-10-producing CD191B2201 B cells. As
Breg are also defined by coexpression of CD1d and
CD5, we also examined CD191CD1dhiCD51 B
cells (B10 cells).9 VLA-4 deficiency itself did not alter
B-cell IL-10 production (figure 3A) or the numbers of
CD191CD1dhiCD51 cells (figure 3B) in naive
mice. CD191IL-101 B cells were detected in the
CNS of control mice with MOG p35-55-induced
EAE (figure 3C, left panel), which reflected 2.9%
of all CNS B cells. In contrast, virtually no IL-101
Breg were detectable in CD19cre/a4f/f mice with
MOG p35-55-induced EAE (figure 3C, left panel).
CNS CD191CD1dhiCD51 B cells were similarly
affected (figure 3D, left panel). Specifically, there
was an 18-fold reduction in the number of
CNS CD1dhiCD51 CNS CD191 B cells in
CD19cre/a4f/f mice with MOG p35-55-induced
EAE in comparison to control mice with EAE. Of
interest, while the absolute numbers of CNS Breg were
reduced in CD19cre/a4f/f mice with MOG p35-55-
induced EAE, the percentage of Breg among CNS B
cells in CD19cre/a4f/f mice and control mice was not
significantly different, indicating that although B-cell
VLA-4 deficiency reduced CNS B-cell accumulation,
it did not selectively influence Breg accumulation. In
comparison to MOG p35-55-induced EAE, very few
IL-101 or CD1dhiCD51 CNS Breg were detected in
rhMOG-induced EAE, and those numbers were not
significantly different in control and CD19cre/a4f/f
mice (figure 3, C and D, right panels).
DISCUSSION In this report, we evaluated the role of
B-cell VLA-4 in EAE induced by MOG p35-55, a
widely used encephalitogen that activates MOG-
specific T cells, but does not efficiently activate
MOG-specific B cells.2,3 Similar to B-cell-deficient
mice4,5 or wild-type mice treated with anti-CD20-
depleting antibodies,3,6 mice selectively deficient in
B-cell VLA-4 expression developed more severe
MOG p35-55-induced EAE. Activated or memory
B cells may secrete proinflammatory cytokines,
whereas unactivated or naive B cells more likely
produce anti-inflammatory cytokines.3,10 Thus, it
is thought that exacerbation of myelin peptide-
induced EAE in B-cell-deficient mice or anti-
CD20-treated wild-type mice may reflect a relative
lack of B-cell regulation.3,5,6 Here, we observed that
B-cell VLA-4 deficiency did not significantly
alter peripheral or CNS T-cell responses in MOG
p35-55-induced EAE. B-cell VLA-4 deficiency
reduced the absolute numbers of all CNS B cells,
including Breg, in MOG p35-55-induced EAE.
Thus, as we have observed for B cells in general in
rhMOG-induced EAE,1 CNS accumulation of Breg
is also VLA-4-dependent. These observations raise
the possibility that CNS Breg contribute to immune
modulation in situ.
While fewer CNS Breg were detected in B-cell VLA-
4-deficient mice, it is not clear whether that association
alone was responsible for the exacerbation of MOG
p35-55-induced EAE. The numbers of CNS infiltrating
CD191IL-101 or CD191CD1dhiCD51 B cells in
MOG p35-55-induced EAE were low, making it
challenging to isolate sufficient numbers to evaluate
how CNS Breg may influence polarization of myelin
antigen–specific T cells ex vivo. Of interest, CNS Th17
cells tended to be higher in CD19cre/a4f/f mice that
manifested exacerbated MOG p35-55-induced EAE,
suggesting that CNS B cells may participate in CNS
T-cell polarization. In 2010, by studying CD20-
mediated B-cell depletion in EAE, it was first demon-
strated that B cells influence M1/M2 monocyte
polarization.3 Subsequent studies of CD20-mediated
depletion in neuromyelitis optica (NMO)11 and
MS11,12 similarly showed that B cells may influence
proinflammatory cytokine production by myeloid
cells. Thus, it is possible that CNS Breg could pro-
mote immune regulation directly or through interac-
tion with T cells, infiltrating monocytes and
macrophages, or resident glial cells, including microg-
lia. Further, our finding that B-cell VLA-4-deficiency
reduces CNS Breg may be relevant to the observa-
tions that natalizumab treatment can exacerbate
symptoms of NMO,13 a humoral-mediated CNS
autoimmune disease that involves CNS infiltration
of immune cells, including B cells.14
EAE induction in B-cell VLA-4-deficient mice by
MOG protein or peptide resulted in paradoxical clin-
ical outcomes. These results are not necessarily unex-
pected. However, investigators may question whether
Figure 2 legend, continued:
and 3 control mice (right). **p # 0.01; ns 5 not significant; unpaired t test. (C, D) CNS-infiltrating Th1 (interferon [IFN]–g-
secreting) and Th17 (interleukin [IL]–17A-secreting) cells (C) and CD251FoxP31 Treg (D) were measured by intracellular
cytokine staining (ICS). Flow cytometry plots (gated on viable CD41 T cells) show 1 representative mouse per group (n 5 6
mice/group; pooled from 2 independent experiments). Data shown in graphs represent mean frequency (%)6 SEM. ns5 not
significant; unpaired t test.
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MOG protein or p35-55 is the better encephalitogen
for EAE studies. Although EAE induced by either
MOG protein or p35-55 does not adequately reflect
the pathogenesis of MS, a spontaneous disease, each
one of these models has features that are advantageous
for studying individual aspects of B-cell participation
in CNS autoimmunity. In general, B cells and anti-
bodies recognize conformational determinants of pro-
tein molecules and, unlike T cells, do not necessarily
recognize linear peptide sequences. Thus, it may be
beneficial to employ MOG protein-induced EAE
for evaluation of antigen-specific B-cell and antibody
responses. While proinflammatory B cells and Breg
may coexist, data suggest that there is a proinflamma-
tory B-cell bias in MS.10,15 Immunization with MOG
protein activates B cells and elicits proinflammatory
cytokine production. Further, in a manner similar to
the benefit observed in anti-CD20 B-cell depletion of
MOG protein-induced EAE, results from clinical tri-
als indicate that anti-CD20 B-cell depletion has ben-
eficial therapeutic effects in relapsing-remitting
MS.16,17 In contrast, EAE induction with MOG
p35-55, which does not efficiently activate proinflam-
matory MOG-specific B cells, may be advantageous
when evaluating B cells in regulation of CNS auto-
immunity. Our results from studying B-cell VLA-4
Figure 3 CNS accumulation of regulatory B cells (Breg) is very late antigen-4 (VLA-4)-dependent
(A, B) B-cell VLA-4 expression did not influence CD191IL-101 (A) or CD1dhiCD51 (B) Breg in naive mice. Spleen cells were
collected from naive CD19cre/a4f/f or control mice (n 5 3 mice/group). Interleukin (IL)–10-producing Breg were gated on
viable CD45hiCD11b2CD191B2201 lymphocytes and CD1dhiCD51 Breg were gated on viable CD45hiCD191 lympho-
cytes. Data are representative of 2 independent experiments. Each flow cytometry plot shows 1 representative mouse
each. (C, D) Evaluation of B-cell VLA-4 expression on CNS CD191IL-101 (C) and CD1dhiCD51 (D) Breg in experimental
autoimmune encephalomyelitis induced by either myelin oligodendrocyte glycoprotein (MOG) p35-55 or recombinant extra-
cellular domain of human MOG protein (rhMOG). CD19cre/a4f/f and control mice were immunized with either MOG p35-55
(n5 4–6 mice/group) or rhMOG (n5 3 mice/group). CNS tissues were collected at peak disease. Data are representative of
2 independent experiments. Data graphs represent mean percentage (%) or total number 6 SEM. **p # 0.01; ns 5 not
significant; unpaired t test (A, B) or Mann-Whitney U test (C, D).
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deficiency in EAE induced by MOG protein and
MOG peptide underscore the need to consider care-
fully the encephalitogen that is used when studying
B-cell physiology in a model of CNS autoimmunity.
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